Table 1. Main characteristics of all the studies included in the meta-analysis.

Study cohort	Year	country	Ethnicity	Duration	No. patients	Age (years)	Histology	Stage	Grade	Treatment	Follow-up (momths)	Cut-off value	HR	Outcome	NOS score
Asher V [33]	2011	USA	Caucasian	1988-1998	235	NR	Mixed	I-IV	1-3	S+C	60	4	U/M	OS	8
Badora-Rybicka A [34]	2016	Poland	Caucasian	2007-2013	315	54(22-77)	Epithelial	I-IV	1-3	S+C	93.7	2.3	M	OS,PFS	6
Cho H [35]	2009	South Korea	Asian	2003-2006	192	52 (NA)	Epithelial	I-IV	1-3	S+C	20.9	2.6	U/M	OS	7
Eo WK [36]	2015	South Korea	Asian	2006-2013	234	56(14-84)	Epithelial	I-IV	1-3	S+C	60	4.28	U	OS,PFS	6
Feng Z [37]	2016	China	Asian	2005-2013	875	53 (30-90)	Serous	I-IV	1-3	S+C	29	2.6	M	OS,PFS	7
Gungorduk K [38]	2015	Turkey	Caucasian	1996-2011	91	57 (32-81)	PFTC	I-IV	1-3	S+C	34	2.7	U/M	OS,PFS	5
Kim HS [39]	2015	South Korea	Asian	1997-2012	109	53 (30-86)	Clear Cell	NR	NR	S+C	46	2.8	U/M	OS,PFS	7
Li Z [40]	2017	USA	Caucasian	2000-2010	654	63 (28-93)	Epithelial	I-IV	1-3	S+C	60	5.25	U/M	OS,PFS	8
Miao Y [41]	2016	China	Asian	2005-2010	344	55 (45-84)	Epithelial	I-IV	1-3	S+C	72	3.02	U/M	OS,PFS	6
Paik E [42]	2016	Korea	Asian	2002-2012	674	51 (15-84)	Epithelial	I-IV	1-3	S+C	52.5	3.91	U/M	OS, PFS	7
Thavaramara T [43]	2011	Thailand	Asian	2004-2009	129	50 (NA)	Epithelial	I-IV	1-3	S+C	NG	2.6	M	OS, PFS	6
Wang Y [44]	2015	China	Asian	2009-2010	126	NR	Serous	I-IV	1-3	S+C	41.3	3.77	U/M	OS,PFS	7
Wang YQ [45]	2016	China	Asian	2006-2013	143	52 (NA)	Mixed	I-IV	1-3	S+C	60	3.43	U/M	OS,PFS	5
Williams KA [46]	2014	USA	Caucasian	1992-2013	519	NR	Mixed	I-IV	1-3	S+C	68	3.6	U/M	OS	6
Zhang WQ [47]	2014	China	Asian	2007-2009	80	55 (27-83)	Epithelial	I-IV	1-3	S+C	45	3.8	U/M	OS	7
Zhang WW [48]	2015	China	Asian	2000-2012	190	51 (24-76)	Mixed	I-IV	1-3	S+C	43	3.4	U/M	OS,PFS	7

HR: hazard ratio; NOS: Newcastle Ottawa Scale; NR: not reported; S: Surgery; C: Chemotherapy; U: univariate; M: multivariate; OS: overall survival; PFS: Progression free survive; PFTC: primary fallopian tube carcinoma.